AlphaYou
Overview
Smart money at a glance
Filings to Oct 8, 2026Net selling: insiders sold $40K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$40K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 7- Open
- $2.00
- 52-wk high
- $3.56
- High
- $2.07
- 52-wk low
- $1.27
- Low
- $1.85
- Prev close
- $1.98
- Mkt cap
- $79.7M
- Volume
- 158.7K
- Beta
- 1.93
- P/B
- 1.0x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -64.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ACRV filings
Are insiders buying or selling Acrivon Therapeutics, Inc. Common Stock (ACRV) stock?
Net selling: insiders sold $40K and bought $0 of ACRV stock on the open market in the 90 days to Oct 8, 2026, according to SEC Form 4 filings. The largest was Blume-Jensen, Peter (President and CEO), who sold $34K. The latest filing was on Oct 7, 2026.
Which members of Congress have traded ACRV recently?
None. No member of Congress disclosed a ACRV trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ACRV smart-money data?
This summary uses filings available on Oct 8, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ACRV right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 12.2% above what analysts expected.
Last report
Aug 12, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.49 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 12, 2026 | -$0.43 / -$0.49Alpha Vantage | +12.24% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 13, 2026 | -$0.49 / -$0.52Alpha Vantage | +5.77% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 19, 2026 | -$0.49 / -$0.46Alpha Vantage | -7.39% miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 13, 2025 | -$0.47 / -$0.58Alpha Vantage | +18.97% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 13, 2025 | -$0.55 / -$0.58Alpha Vantage | +5.17% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 14, 2025 | -$0.51 / -$0.65Alpha Vantage | +21.54% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 27, 2025 | -$0.60 / -$0.77Alpha Vantage | +22.08% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 13, 2024 | -$0.59 / -$0.59Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 12, 2026, in 35 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $80M
Valuation
- P/B1.02
Quality
- Operating margin0.0%
- ROE-64.6%
- ROA-38.0%
Growth
- Beta1.93
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
40 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace